COST-EFFECTIVENESS STUDY OF SECOND LINE THERAPIES IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN

被引：1

作者：

Arlandis, S. ^{[1
]}

Castro, D. ^{[2
]}

Errando, C. ^{[3
]}

Fernandez, E. ^{[4
]}

Jimenez, M. ^{[4
]}

Gonzalez, P. ^{[5
]}

Crespo, C. ^{[6
]}

Stauble, F. ^{[7
]}

Rodriguez, J. M. ^{[5
]}

Brosa, M. ^{[6
]}

机构：

[1] Hosp Univ La Fe, Dept Urol, Valencia, Spain

[2] Hosp Univ Canarias, Dept Urol, Santa Cruz de Tenerife, Spain

[3] Fundacio Puigvert, Dept Urol, Barcelona, Spain

[4] Hosp Ramon & Cajal, Dept Urol, E-28034 Madrid, Spain

[5] Medtronic, Dept Hlth Econ & Reimbursement, Madrid, Spain

[6] Oblikue Consulting, Dept Hlth Econ, Barcelona, Spain

[7] Medtronic, Dept Hlth Econ & Reimbursement, Tolochenaz, Switzerland

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2009年 / 8卷 / 04期

关键词：

D O I：

10.1016/S1569-9056(09)60070-1

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：136 / 136

页数：1

共 50 条

[1] A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN
Arlandis, S.
Castro, D.
Errando, C.
Fernandez, E.
Jimenez, M.
Gonzalez, P.
Crespo, C.
Stauble, F.
Rodriguez, J. M.
[J]. GACETA SANITARIA, 2009, 23 : 200 - 201
[2] Cost-Effectiveness of Third-Line Therapies for Overactive Bladder
Cohen S.A.
[J]. Current Bladder Dysfunction Reports, 2018, 13 (3) : 153 - 157
[3] Cost-effectiveness of novel therapies for overactive bladder
Mayr, Craig A.
Shepherd, Jonathan P.
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) : 527 - 535
[4] Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder
Leong, Randall K.
de Wachter, Stephan G. G.
Joore, Manuela A.
van Kerrebroeck, Philip E. V.
[J]. BJU INTERNATIONAL, 2011, 108 (04) : 558 - 564
[5] COST-EFFECTIVENESS OF SACRAL NEUROMODULATION AND BOTULINUM TOXIN-A FOR PATIENTS WITH REFRACTORY IDIOPATHIC OVERACTIVE BLADDER
Clemens, J. Quentin
Anger, Jennifer T.
Ganz, Michael L.
Denevich, Svetlana
Shah, Dhvani
Carlson, Angeline M.
Wittek, Michael R.
Pashos, Chris L.
[J]. NEUROUROLOGY AND URODYNAMICS, 2012, 31 (02) : 223 - 223
[6] COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE BLADDER
Malone, D. C.
Armstrong, E. P.
Bui, C.
[J]. VALUE IN HEALTH, 2012, 15 (04) : A155 - A155
[7] Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
Arlandis-Guzman, Salvador
Errando-Smet, Carlos
Trocio, Jeffrey
Arumi, Daniel
Rejas, Javier
[J]. BMC UROLOGY, 2011, 11
[8] Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
Salvador Arlandis-Guzman
Carlos Errando-Smet
Jeffrey Trocio
Daniel Arumi
Javier Rejas
[J]. BMC Urology, 11
[9] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
Jonathan P. Shepherd
Charelle M. Carter-Brooks
Christopher Chermanksy
[J]. International Urogynecology Journal, 2018, 29 : 1213 - 1219
[10] A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
不详
[J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) : 629 - 630

← 1 2 3 4 5 →